Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis
about
Development and evaluation of an algorithm to identify users of Prolia(®) during the early postmarketing period using health insurance claims data.Effects of RANKL-Targeted Therapy in Immunity and Cancer.Positive predictive values of International Classification of Diseases, 10th revision codes for dermatologic events and hypersensitivity leading to hospitalization or emergency room visit among women with postmenopausal osteoporosis in the Danish anPositive predictive values of ICD-10 codes to identify incident acute pancreatitis and incident primary malignancy in the Scandinavian national patient registries among women with postmenopausal osteoporosis.Predictive values of diagnostic codes for identifying serious hypocalcemia and dermatologic adverse events among women with postmenopausal osteoporosis in a commercial health plan database.
P2860
Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Design and methods of a postma ...... of postmenopausal osteoporosis
@ast
Design and methods of a postma ...... of postmenopausal osteoporosis
@en
Design and methods of a postma ...... ng long-term safety of Prolia®
@nl
type
label
Design and methods of a postma ...... of postmenopausal osteoporosis
@ast
Design and methods of a postma ...... of postmenopausal osteoporosis
@en
Design and methods of a postma ...... ng long-term safety of Prolia®
@nl
prefLabel
Design and methods of a postma ...... of postmenopausal osteoporosis
@ast
Design and methods of a postma ...... of postmenopausal osteoporosis
@en
Design and methods of a postma ...... ng long-term safety of Prolia®
@nl
P2093
P2860
P356
P1476
Design and methods of a postma ...... of postmenopausal osteoporosis
@en
P2093
Catherine Stehman-Breen
Cathy W Critchlow
Christine Haller
Denosumab Global Safety Assessment Team
Leonid Katz
Rachel B Wagman
P2860
P304
P356
10.1002/PDS.3477
P577
2013-07-15T00:00:00Z